07th week of 2011 patent applcation highlights part 24 |
Patent application number | Title | Published |
20110038831 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2011-02-17 |
20110038832 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE - Provided herein are methods of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof. | 2011-02-17 |
20110038833 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 2011-02-17 |
20110038834 | NOVEL AVIAN CYTOKINES AND GENETIC SEQUENCES ENCODING SAME - The present invention relates generally to novel recombinant polypeptides having avian cytokine properties and to genetic sequences encoding same. More particularly, the present invention is directed to recombinant avian Type III interferon polypeptides, and genetic sequences encoding same, together with cellular expression systems and uses for same. Even more particularly, the present invention is directed to avian interferon-λ (IFN-λ) and functional derivatives, homologues and fragments thereof and to methods of use thereof. The molecules and cells of the present invention are useful in a wide range of applications including, but not limited to, providing a means for the treatment and prophylaxis of disease conditions, in particular avian disease conditions, or for use as an immune response modulator. Also provided are diagnostic means for screening for immune response and screening means for identifying modulators of IFN-λ protein or nucleic acid functionality. | 2011-02-17 |
20110038835 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (I): wherein variable are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided. | 2011-02-17 |
20110038836 | Device and Method for Transfecting Cells for Therapeutic Use - This invention generally relates to devices and methods for transfection of living cells using electroporation, in particular high throughput microtluidic electroporation, and to therapeutic uses of the transfected cells. | 2011-02-17 |
20110038837 | COMPOSITION FOR IMPROVING INTESTINAL MICROFLORA - The present invention is to provide a composition for improving the intestinal microflora for maintaining a good intestinal microflora. The present invention consists of a composition for improving the intestinal microflora characterized by containing | 2011-02-17 |
20110038838 | Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases - Embodiment include methods for treating cats and dogs with inflammatory bowl disease or inflammatory-like bowl disease or immune mediated hemolytic anemia or atopic dermatitis which are being treated with steroids or immune suppressors which involves the step of administering to the animal a probiotic comprised of | 2011-02-17 |
20110038839 | Composition of Entomopathogenic Fungus and Method of Production and Application for Insect Control - Microsclerotia of entomopathogenic fungi, including | 2011-02-17 |
20110038840 | DISINFECTANT COMPOSITION COMPRISING PHAGE - The present invention provides a disinfectant composition including a phage of | 2011-02-17 |
20110038841 | Multi-Transgenic Pigs for Diabetes Treatment - The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (αGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided. | 2011-02-17 |
20110038842 | High affinity ny-eso t cell receptor - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 2011-02-17 |
20110038843 | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment - Disclosed herein are methods and materials for inhibiting tumor growth by administering viral vectors to tumor cells. Particularly exemplified herein are methods of inhibiting tumor growth of colon tumors by delivering 15-PGDH to tumor environment. Antigen presenting cells may be coadministered with 15-PGDH. | 2011-02-17 |
20110038844 | COMPOSITIONS FOR TREATING AN ARTHRITIC CONDITION - The present invention relates to compositions comprising human Tr1 cells directed to a joint-associated antigen and methods for treating an arthritic condition. | 2011-02-17 |
20110038845 | Diagnosis and treatment for endometriosis - The invention relates to detection of individuals having or at risk of developing endometriosis based on the presence of one or more polymorphism in a gene associated with the fibrinolytic pathway, and methods for treating or preventing endometriosis by modulating the fibrinolytic pathway. | 2011-02-17 |
20110038846 | PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION FOR TREATING A BRAIN TUMOR, PRODUCTION PROCESS THEREOF AND A KIT OF PARTS COMPRISING THE PHARMACEUTICAL COMPOSITION - The invention relates to the pharmaceutical composition for the treatment of a brain tumor, which contains in an effective amount from pharmaceutical point of view Peptidtoxin from spiders, | 2011-02-17 |
20110038847 | PROCESS FOR PREPARING BIOABSORBABLE SHEET PREPARATION HOLDING THROMBIN - A process for preparing a bioabsorbable sheet preparation holding thrombin is provided. A process for preparing a bioabsorbable sheet preparation holding thrombin which comprises immersing a bioabsorbable sheet consisting of polyglycolic acid in a thrombin solution containing thrombin as an active ingredient, glycerol as a softening agent, Tween 80 as a permeating agent, and optionally histidine and trehalose as a stabilizing agent followed by drying to hold thrombin on said bioabsorbable sheet, and a bioabsorbable sheet preparation holding thrombin prepared by said process. | 2011-02-17 |
20110038848 | DIETARY SUPPLEMENT COMPOSITIONS FOR CARDIOVASCULAR HEALTH - This document provides dietary supplements. For example, composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health as well as methods for reducing cholesterol and improving overall cardiovascular health are provided. | 2011-02-17 |
20110038849 | INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATING CANCER - Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ. | 2011-02-17 |
20110038850 | G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders - The present invention relates to methods of using BRS-3 to screen candidate compounds as compounds suitable for the treatment of sleep-related disorders. Inverse agonists and antagonists of the invention are useful as therapeutic agents for promoting sleep and for preventing or treating sleep disorders ameliorated by promoting sleep, such as insomnia and the like. Agonists and partial agonists of the invention are useful as therapeutic agents for promoting wakefulness and for preventing or treating excessive sleepiness, such as excessive sleepiness associated with narcolepsy and the like. The invention further relates to methods of using a BRS-3 to screen candidate compounds as pharmaceutical agents for a GABA-related neurological disorder such as a sleep disorder, an anxiety disorder, a convulsive disorder, migraine, a depressive disorder, a psychotic disorder, or a cognitive disorder. Compounds of the invention encompass compounds having sleep-promoting, wakefulness-promoting, anxiolytic, anticonvulsant, antidepressant, antipsychotic, and cognition-enhancing activities. | 2011-02-17 |
20110038851 | TREATMENT OF SYNUCLEINOPATHIES - This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods. | 2011-02-17 |
20110038852 | ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION CHANNELS - This invention provides methods for preventing or treating infection by viruses, in particular an influenza virus by modulating transporters, carriers, and ion channels. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in order to select agents which can inhibit viral infection are described herein. The method employs a siRNA screening platform and uses gene silencing to map the ‘viral infectome’—a compilation of cellular proteins that the virus needs to establish infection and drive the infectious cycle. Charting the infectome provides information on the viral biology by the identification of host cell proteins involved in viral infection and allows the development of novel anti-viral drugs that prevent the viruses from establishing productive infection in cells. | 2011-02-17 |
20110038853 | Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis - The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent. | 2011-02-17 |
20110038854 | STRATEGY FOR HOMO- OR HETERO-DIMERIZATION OF VARIOUS PROTEINS IN SOLUTION AND IN CELL - The present invention describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises an intracellular region and a transmembrane region; and a second portion comprising a dimerization domain. The present invention also describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises a receptor extracellular region; and a second portion comprising a dimerization domain, wherein the dimerization domain comprises an antibody heavy chain region of a Fab fragment or an antibody light chain region. Polynucleotides encoding the chimeric polypeptides and methods of use of the chimeric polypeptides are also described. | 2011-02-17 |
20110038855 | TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL - Methods of modulating a T cell response are provided. Methods include, among other things, contacting a T cell that expresses TNF-related apoptosis-inducing ligand (TRAIL, Apo-2L) or TRAIL receptor (DR4 or DR5) with a molecule that binds to TRAIL (Apo-2L), a molecule that binds to TRAIL receptor (DR4 or DR5), or with a soluble TRAIL (Apo-2L) reagent. | 2011-02-17 |
20110038856 | METHODS OF TREATING NEOPLASTIC, AUTOIMMUNE AND INFLAMMATORY DISEASES - Methods of treating cancer and autoimmune and inflammatory diseases are provided. | 2011-02-17 |
20110038857 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE - The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 2011-02-17 |
20110038858 | METHODS OF TREATING HEMATOLOGIC CANCERS USING PNP INHIBITORS SUCH AS FORODESINE IN COMBINATION WITH ALKYLATING AGENTS OR ANTI-CD20 AGENTS - The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits. | 2011-02-17 |
20110038859 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2011-02-17 |
20110038860 | METHODS FOR INHIBITION OF POLYCLONAL B CELL ACTIVATION AND IMMUNOGLOBULIN CLASS SWITCHING TO PATHOGENIC AUTOANTIBODIES BY BLOCKING CD1-MEDIATED INTERACTIONS - Pathogenic polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies is inhibited by binding molecules that specifically interfere with CD1 antigen, but do not activate signaling (blocking agents), or by molecules that bind to the T cell antigen receptor on T cells that recognize CD1. When CD1 mediated signaling is thus blocked, the T cell response is diminished, resulting in reduced polyclonal B cell activation and reduced immunoglobulin class switching to pathogenic autoantibodies. | 2011-02-17 |
20110038861 | Methods of Treating Alzheimer's Disease Using Antibodies Directed Against Amyloid Beta Peptide and Compositions Thereof - Monoclonal antibodies directed against amyloid beta peptide and methods of using same for treatment and prevention of Alzheimer's disease and Down's syndrome are described. | 2011-02-17 |
20110038862 | METHOD AND KIT FOR THE DETECTION OF GENES ASSOCIATED WITH PIK3CA MUTATION AND INVOLVED IN PI3K/AKT PATHWAY ACTIVATION IN THE ER-POSTITIVE AND HER2-POSITIVE SUBTYPES WITH CLINICAL IMPLICATIONS - A method to determine the clinical outcome of breast tumour affecting a patient if treated with an antitumoural agent against breast tumour. The method includes the step of assaying a sample of a breast tumour from the patient for an expression level of selected genes, by contacting mRNA sequences from the cells of this breast tumour with a set of more than 3 nucleotide sequences related to human mutated PIK3CA. | 2011-02-17 |
20110038863 | METHODS AND COMPOSITIONS FOR IMPROVING RECOMBINANT PROTEIN PRODUCTION - Nucleic acid molecules modified to enhance recombinant protein, e.g., antibody, expression and/or reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing proteins devoid of mis-spliced and/or intron read-through by-products by the use of such vectors in host cells under cell culture conditions suitable for recombinant protein expression. | 2011-02-17 |
20110038864 | Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof - Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. | 2011-02-17 |
20110038865 | ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS - Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules. | 2011-02-17 |
20110038866 | IMPROVED FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF - The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications. | 2011-02-17 |
20110038867 | REMEDIES FOR PEMPHIGUS CONTAINING ANTI FAS LIGAND ANTIBODIES - Disclosure of the use of FasL antagonists, e.g. of humanized antibodies directed against human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL) for the prevention and/or treatment of skin diseases associated with keratinocytes acantholysis, particularly for the prevention and/or treatment of pemphigus. | 2011-02-17 |
20110038868 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders. | 2011-02-17 |
20110038869 | MONOCLONAL ANTIBODIES AGAINST CD32B - Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 2011-02-17 |
20110038870 | COMPOSITIONS AND METHODS TO ENHANCE THE IMMUNE SYSTEM - The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha. | 2011-02-17 |
20110038871 | CCR2 INHIBITORS FOR TREATING CONDITIONS OF THE EYE - Disclosed herein are compositions and methods for treating conditions of the eye using CCR2. | 2011-02-17 |
20110038872 | METHODS OF DIAGNOSING AND TREATING AUTISM - The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers. | 2011-02-17 |
20110038873 | MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TLX) - The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs. | 2011-02-17 |
20110038874 | ANTI-VEGFR MONOCLONAL ANTIBODY, METHOD OF MAKING AND USES THEREOF - The subject invention is directed to a VEGFR2 (vascular endothelial growth factor receptor II) monoclonal antibody (mAb), and the amino acid sequence of the heavy chain and the light chain of the mAb. The invention is also directed to methods for making the VEGFR2 mAb, and methods of using the mAb to inhibit angiogenesis and treat various conditions such as tumor and retinal diseases. | 2011-02-17 |
20110038875 | HEMATOPOIETIC CELLS EXPRESSING THE PROTEIN SUSD3 AND LIGANDS FOR THE PROTEIN SUSD3 - The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein SUSD3 on the surface of said cells, to methods for preparing said cells and to ligands for SUSD3. | 2011-02-17 |
20110038876 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. | 2011-02-17 |
20110038877 | INTERLEUKIN-6 ANTAGONISTS - The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention. | 2011-02-17 |
20110038878 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 2011-02-17 |
20110038879 | IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES - Compositions for preventing and/or treating | 2011-02-17 |
20110038880 | PARASPORIN-1 RECEPTOR AND USE THEREOF - The receptor of parasporin-1 has been found to be beclin-1. Based on the finding, the present invention provides a method of determining the sensitivity of a cell to parasporin-1, comprising measuring the expression level of beclin-1 polypeptide on the cell membrane or in a membrane fraction of a cell; an inhibitor of the cytotoxicity of parasporin-1, containing beclin-1 polypeptide etc.; a method of screening for a substance capable of inhibiting the cytotoxicity of parasporin-1, comprising evaluating the degree of binding of parasporin-1 to beclin-1 polypeptide in the presence of a test substance; a cell death inducer containing an antibody that specifically recognizes beclin-1 polypeptide; a method of screening for a substance capable of inducing cell death, comprising evaluating the binding of a test substance to beclin-1 polypeptide, and the like. | 2011-02-17 |
20110038881 | PROGNOSTIC ASSAY FOR DETERMINING T CELL RESPONSE TO HLA ANTIGENS AND USE THEREOF IN FIELD OF TISSUE TRANSPLANTATION - The invention provides an in vitro method of determining whether an individual is at risk of, or undergoing, graft damage or rejection of immune origin and/or damage of immune origin to non-graft tissue using polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. | 2011-02-17 |
20110038882 | Methods for Treating Allergic Disease - A method for treating or alleviating allergic disease in a mammal in need thereof having administering to the mammal a therapeutically effective amount of a pharmaceutical composition having phycocyanin is provided. A method for modulating balance between Th1 and Th2 immune response in a mammal in need thereof, having administering to the mammal an effective amount of phycocyanin, wherein immune response of the mammal is skewed toward the Th1 immune response is also provided. Phycocyanin from | 2011-02-17 |
20110038883 | HE4 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 2011-02-17 |
20110038884 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST - An EP1 agonist has an immunopotentiating effect mediated by cytotoxic T lymphocyte activation and/or natural killer cell activation, and is thus useful for the prevention and/or treatment of cancers, microbial infectious diseases and the like. | 2011-02-17 |
20110038885 | CHEMOKINE ANALOGS - The present invention is directed to peptide analogs of chemokine, the pharmaceutically acceptable salts thereof, to methods of using such analogs to treat mammals and to pharmaceutical compositions useful therefor comprising said analogs. | 2011-02-17 |
20110038886 | N-Linked Glycosylation Alteration in E0 and E2 Glycoprotein of Classical Swine Fever Virus and Novel Classical Swine Fever Virus Vaccine - E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). E2 is involved in several functions including virus attachment and entry to target cells, production of antibodies, induction of protective immune response in swine, and virulence. Seven putative glycosylation sites in E2 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E2 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all putative glycosylation sites in E2, but restored when mutation N185A reverted to wild-type asparagine produced viable virus that was attenuated in swine. Single mutations of each of the E2 glycosylation sites showed that amino acid N116 (N1v virus) was responsible for BICv attenuation. N1v efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection suggesting that glycosylation of E2 could be modified for development of CSF live-attenuated vaccines. Additionally, a new developed virus, contained deletions of putative glycosylation sites N1 in E2 and N1 in E0 (6b), called N1E0/2v, induce a solid protection against the challenge at 3 and 28 days post-inoculation. | 2011-02-17 |
20110038887 | Novel Vaccine Against Trypanosoma Cruzi Infection - The present invention relates to a vaccine against | 2011-02-17 |
20110038888 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER - An adjuvant composition comprising polyIC and a cationic polymer; the cationic polymer comprising from about 100 to about 500 amino acid residues, wherein the mass:mass ratio of the polyIC:cationic polymer is from about 4:1.5 to about 4:3 is described. | 2011-02-17 |
20110038889 | METHODS AND COMPOSITIONS FOR ALTERING CELL FUNCTION - The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not. | 2011-02-17 |
20110038890 | Cellular And Viral Inactivation - The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal. | 2011-02-17 |
20110038891 | NOVEL LACTIC ACID BACTERIUM HAVING ANTI-ALLERGIC ACTIVITY, ANTI-ALLERGIC AGENT, FOOD AND PHARMACEUTICAL COMPOSITION EACH COMPRISING THE LACTIC ACID BACTERIUM, AND PROCESS FOR PRODUCTION OF THE ANTI-ALLERGIC AGENT - An object aims to develop a lactic acid bacterium having an anti-allergic activity, which can be grown by using rice, particularly polished white rice, and can be collected, cooked and ingested together with rice in such a state that the lactic acid bacterium is attached to the surface of the rice. Another object aims to develop a food composition and a pharmaceutical composition, each of which comprises rice containing the lactic acid bacterium as a material. Thus, disclosed are: a lactic acid bacterium | 2011-02-17 |
20110038892 | COMPLEXING SYSTEM - The invention relates to a complexing system comprising two polypeptide helices derived from a SNAP protein; one polypeptide helix derived from syntaxin; one polypeptide helix derived from synaptobrevin or a homolog thereof; and one or more cargo moieties attached to the polypeptide helices, wherein the four polypeptide helices can form a stable SNARE complex. The invention also relates to a method of producing the complexing system and the use of the complexing system. | 2011-02-17 |
20110038893 | THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN ASSOCIATED WITH DIABETIC NEUROPATHY - The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration. | 2011-02-17 |
20110038894 | Immunogenic Peptides of Tumor Associated Antigen L6 and Uses Thereof in Cancer Therapy - An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide. The immunopeptide and its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6. | 2011-02-17 |
20110038895 | MULTI-EPITOPE PEPTIDE-LOADED DENDRITIC CELL IMMUNOTHERAPY FOR CANCER - The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen. | 2011-02-17 |
20110038896 | Biodegradable immunomodulatory formulations and methods for use thereof - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier. | 2011-02-17 |
20110038897 | ORAL CONTROLLED RELEASE FORMULATIONS - This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy. | 2011-02-17 |
20110038898 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine by using said composition is also provided. | 2011-02-17 |
20110038899 | Pharmaceutical Solutions and Method for Solublilizing Therapeutic Agents - Pharmaceutical solutions containing hydrophobic or lipophilic therapeutic agents and methods for producing the same are provided. Pharmaceutical solutions of the invention are produced by dissolving the therapeutic agent in one or more tocopherols or tocotrienols and one or more alcohols or glycols. These solutions are used to produce pharmaceutical compositions. | 2011-02-17 |
20110038900 | NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS - In various aspects of the present invention, nanoparticle compositions are provided which comprise (a) nanoparticles comprising at least one biodegradable polymer and (b) at least one pharmaceutical associated with the nanoparticles. In other aspects of the present invention, methods of forming nanoparticles compositions are provided, which comprise contacting a first liquid that comprises one or more biodegradable polymers dissolved in a first solvent with a second liquid that comprises a second solvent which is miscible with the first solvent while being a non-solvent for the one or more biodegradable polymers, such that nanoparticles are formed. | 2011-02-17 |
20110038901 | Method for Gentle Mechanical Generation of Finely Dispersed Micro-/Nano-Emulsions with Narrow Particle Size Distribution and Device for Carrying Out Said Method - This invention relates to a method for the mechanically protective production of finely dispersed micro-/nanoemulsions with narrow droplet size distribution, whereby drops are produced on the surface of a membrane or of a filter fabric, and the drops are detached from the membrane or filter fabric surface by motion of the membrane or of the filter fabric in a first immiscible liquid phase in which pronounced stretching flow components in particular, besides shear flow components, bring about the detachment of the drops formed on the membrane surface especially efficiently and protectively. The invention also relates to a device for implementing the method according to the invention with a membrane or filter unit that is positioned to move, in particular to be able to rotate, in a housing with a gap that may be eccentric toward the inner wall of the housing and/or provided with flow baffles that produce stretching flow components. | 2011-02-17 |
20110038902 | ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS AND METHODS FOR MANUFACTURING ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS - Antiperspirant products and methods for manufacturing antiperspirant products are provided herein. In accordance with an exemplary embodiment, an antiperspirant composition comprises a container and an antiperspirant product housed within the container. The antiperspirant product comprises a first portion and a second portion. The first portion comprises an emulsion having a water phase and an oil phase. The oil phase comprises cetyl PEG/PPG-10/1 dimethicone. The second portion has a composition different from the first portion. | 2011-02-17 |
20110038903 | Apparatus and Process for Generating and Harvesting Adult Stem Cells and Fluid Associated with it from Skin and Omentum for Medical, Cosmetic, and Veterinary Use - Apparatus and process to create, expand, and localize the population of stem cells in adult tissues by placing a foreign body either in omentum or in the subcutaneous tissue. The apparatus 1) traps the granulation fluid, cells a fluid rich in a myriad of growth factors, 2) mobilizes and concentrates free-floating stem cells in the granulation fluid, and 3) stimulates the growth of a new tissue around the apparatus, which provides another source of stem cells. Stem cells obtained by this process can be used as freshly isolated or after culturing, which can be used for wound healing, treating diseases, and regenerating organs in animals and humans. The granulation fluid could substitute the stem cells in many of their applications and offers the convenience of an injectable medicine for treating animal and human diseases. | 2011-02-17 |
20110038904 | Gel Product - A gel construct includes a viscoelastic gel pad with migratory oils or also synthetic or triglyceride fluids, emollients, waxes, vitamins, humectants, pharmaceutical actives, and other hair or skin conditioning or treatment agents. The gel construct also includes a body, hair or skin-side layer on one major side surface of the gel pad which is permeable to the migratory agents of the gel. The gel construct optionally includes a barrier layer on the opposite major side surface of the gel pad to prevent the migratory agents of the gel from penetrating that layer. The gel construct may find use as, for example, an insole. | 2011-02-17 |
20110038905 | SKIN ANTI-AGING AGENT FOR EXTERNAL USE - It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises protein nanoparticles containing an active ingredient. | 2011-02-17 |
20110038906 | Aloe powder, aloe juice, and method for producing the same - In the conventional technology, macromolecular polysaccharides, which the aloe vera gel inherently has, are broken down into small molecules for the following reasons: First, cellulose is broken down by the enzyme such as cellulose; Second, agitation in the cellulose breakdown process by the enzyme of cellulase and the like is performed in a heated state for an extended period of time; Third, nearly the same technique is employed also in the aloin absorption process by the activated charcoal; Fourth, a plurality of times of filtering causes intense oxidation to the gel juice. For the reasons described above, the molecular weight of macromolecular polysaccharides, which the aloe vera gel inherently has, is reduced to 80,000 dalton or less. Therefore, by use of the conventional technology, it is impossible to provide macromolecular polysaccharides that the aloe vera gel has in a state where aloin is removed. | 2011-02-17 |
20110038907 | Organic-Coated Synthetic Mica Powder, Production Method Thereof, And Cosmetics Using The Same - The present invention provides an organic-coated synthetic mica powder excellent in feeling in use and water-repellent property by an organic coating layer from an organic surface treatment agent, which is firmly and chemically bound to the surface of the synthetic mica powder, and further provides, when an organosilicone having Si—H groups is used as the organic surface treatment agent, an organic-coated synthetic mica powder having very little hydrogen evolution due to residual Si—H groups. The organic-coated synthetic mica powder can be obtained by a producing method comprising a pretreatment process and a coating process, said pretreatment process comprising: contacting synthetic mica powder and an ammonium ion in water; carrying out solid-liquid separation to remove the liquid phase; and drying the solid phase at 200° C. or lower to volatilize NH | 2011-02-17 |
20110038908 | FORMULATIONS AND METHODS EMPLOYING ANHYDROUS DISINFECTANT - Use of dried compositions of silver dihydrogen citrate along with citric acid in antimicrobial amounts directly as disinfectants is described. | 2011-02-17 |
20110038909 | System and Method for Using Nanoparticles for Antimicrobial Activity - A system and method for using nanoparticles for antimicrobial activity. An antimicrobial coating can be provided, which can include a plurality of discrete first particles that can have an average diameter of less than approximately 400 nanometers and, in a preferred embodiment, 10 nanometers or less. The plurality of discrete first particles can include pure silver metal. In an embodiment, the plurality of discrete first particles can also include a physiologically inert stabilizer. The antimicrobial coating can also include a polymeric film, in which the plurality of discrete first particles can be directly embedded therein. | 2011-02-17 |
20110038910 | ANTI-INFECTIVE ANTIMICROBIAL-CONTAINING BIOMATERIALS - Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of loading them with silver compounds are described. The silver-containing biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided. | 2011-02-17 |
20110038911 | PROSTHETIC MATERIAL FOR LIVING ORGAN - It is an object of the invention to provide a prosthetic material for living organs, which can sufficiently withstand the arterial pressure and thereby can prevent leakage of blood or rupture of blood vessels, and which serves as a scaffold for vascular tissue regeneration, and does not necessitate repeated surgeries or the like. | 2011-02-17 |
20110038912 | COMPOSITIONS AND METHODS FOR DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS TO MEDICAL DEVICE SURFACES - The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions. | 2011-02-17 |
20110038913 | Polymeric endoprostheses with modified erosion rates and methods of manufacture - An erodible prosthesis comprising alternate rates of erosion is disclosed, wherein said alternate rates of erosion can be selectively initiated. Some embodiments according to the invention may comprise an agent for initiating an alternative rate of erosion, such as, for example, a sensitizer, dissolution inhibitor, photo-acid generator, biochemically active additive, thermally activated catalyst, light activated catalyst, electromagnetic radiation activated catalyst, hydration activated catalyst, pH activated catalyst, low melting agent, and/or enzyme activated catalyst. One or more of the foregoing agents may be dispersed within one or more layers. | 2011-02-17 |
20110038914 | CORAL-DERIVED COLLAGEN AND METHODS OF FARMING SAME - An isolated collagen fiber is disclosed, wherein a length of the fiber prior to stretching by about 15%, is identical to a length of the fiber following said stretching by about 15%. The fiber comprises a Nuclear Magnetic Resonance (NMR) spectroscopic profile as shown in FIG. | 2011-02-17 |
20110038915 | Chewing Gum Formula for Enhancing Psycho-Spirituality - The present invention relates to a chewing gum formulation which serves as a means for awakening human consciousness and mindfulness to the sensorial subtleties, which in turn strengthens sovereignty such that overall psycho-spirituality is enhanced. More particularly, this invention relates to a dietary supplement consisting of the botanical plant | 2011-02-17 |
20110038916 | Sanitizers - The present invention provides sanitizer systems for improving personal hygiene and reducing the potential for the spread of disease. The sanitizer systems enable more thorough cleansing by providing mechanically removal of microbial agents and soil from the skin with an absorbent sheet. | 2011-02-17 |
20110038917 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING GRAM-NEGATIVE BACTERIAL INFECTIONS - The present invention relates to therapeutic compositions and methods of treatment that contain or employ at least two of: an oligomeric proanthocyanidin; a protease inhibitor; and/or a lactoferrin. The compositions of this invention may be in various forms depending upon the disease or condition to be treated. The compositions and methods of this invention are useful to treat a patient suffering from or susceptible to gram negative bacterial infections, including those associated with cystic fibrosis, ear infections and with wounds. | 2011-02-17 |
20110038918 | Composition For Transdermal Delivery of Fentanyl - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 2011-02-17 |
20110038919 | TEXTILE MATERIALS WITH ADHESIVE AND METHODS FOR USE THEREOF - Textile materials for management of skin health complications associated with skin folds, as well as adhesives for attaching the materials to the skin of a subject. The adhesive can be supplied separately from the material, for application post-production, or can be applied to the material during production. | 2011-02-17 |
20110038920 | WOUND HEALING COMPOSITIONS AND TREATMENTS - Methods and compositions comprising an anti-ostepontin agent and/or a PDGF receptor blocker or antagonist, alone or in combination with one or more anti-connexin agents, for example, one or more anti-connexin polynucleotides and/or one or more anti-connexin peptides or peptidomimetics, are provided for the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications. | 2011-02-17 |
20110038921 | METHODS AND COMPOSITIONS FOR TEMPORAL RELEASE OF AGENTS FROM A BIODEGRADABLE SCAFFOLD - The present invention provides methods and compositions for sequentially and separately reducing infection and/or inflammation and regenerating tissue at a lesion site, by contacting the lesion site with a biodegradable scaffold that first delivers one or more agents at the lesion site to reduce infection and/or inflammation and then delivers one or more agents to regenerate tissue at the lesion site after inflammation is reduced. | 2011-02-17 |
20110038922 | COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS - This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included. | 2011-02-17 |
20110038923 | ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION - The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g., antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors of these constructs (including, but not limited to, viral vectors), compositions of them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided. | 2011-02-17 |
20110038924 | OSTEOARTHRITIS GENE THERAPY - The present invention relates to methods and compositions for protecting joint cartilage from degradation by inserting transgenes that increase Kras-2b expression or an effector thereof within one or more tissues of the joint. The present invention can thus be used in the treatment and/or prevention of joint diseases and disorders, including but not limited to osteoarthritis. | 2011-02-17 |
20110038925 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 2011-02-17 |
20110038926 | Method of producing a cationic liposomal preparation comprising a lipophilic compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. | 2011-02-17 |
20110038927 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2011-02-17 |
20110038928 | ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN - The present invention is directed to a novel rapidly dissolvable pharmaceutical composition comprising zolmitriptan or pharmaceutically acceptable salts or esters thereof and least one direct compression filler. The pharmaceutical compositions of the present invention can advantageously be prepared in a solid dosage form, e.g. a tablet, utilizing directly compressible ingredients. | 2011-02-17 |
20110038929 | ORAL CARE PET PRODUCT AND METHOD - An effervescent composition for reducing breath odors and preventing and/or reducing plaque buildup, deposits and/or formation on the teeth of pet animals. The effervescent composition includes at least one active agent adapted to reduce or destroy bacteria present in the mouth of the pet animal responsible for causing bad breath and plaque; and an effervescent component including a carbonate containing compound and an acidifying compound. | 2011-02-17 |
20110038930 | HOT-MELT EXTRUDED PHARMACEUTICAL DOSAGE FORM - The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; | 2011-02-17 |